Tetrabenazine is neuroprotective in Huntington's disease mice

Table 1 Design of TBZ trial in YAC128 mice.

Group #	Group name	Number of mice	Mouse genotype	Single dose (50 μl) (three times per week)	Drug dosage (mg/kg)
1	YAC-Ctrl	15	YAC128	50 μl PBS	50 μl PBS
2	YAC-TBZ (Early)	15	YAC128	0.125 mg of TBZ (started at 2 months of age)	5 mg TBZ
3	YAC-TBZ (Late)	15	YAC128	0.125 mg of TBZ (started at 6 months of age)	5 mg TBZ
4	WT-Ctrl	15	WT	50 μl PBS	50 μl PBS
5	WT-TBZ (Early)	15	WT	0.125 mg of TBZ (started at 2 months of age)	5 mg TBZ
6	WT-TBZ (Late)	15	WT	0.125 mg of TBZ (started at 6 months of age)	5 mg TBZ

Six groups of mice were used in our experiments. At 2 months of age, WT and YAC128 mice were divided into three groups each (15 mice in each group, 90 mice total, all females), and drug treatment was initiated. The drugs were fed orally to mice three times a week starting at 2 months of age for early groups and at 6 months of age for late groups. The group number, group name, number and genotype of mice in each group, and dose of single drug treatment (three times/week) are shown for each group. Also shown is the estimated drug dosage in mg/kg. Ctrl, Control; WT, wild type; YAC, YAC128.

ISSN: 1750-1326